Kisunla August 27, 2024 Kisunla: A New Breakthrough for Alzheimer’s Disease The FDA’s approval of Kisunla (donanemab-azbt) marks a significant advancement in the treatment of early-stage Alzheimer’s disease. Kisunla was developed by Eli Lilly, and this new Read More
Compounding Pharmacies vs. Big Pharma: The Battle for Dominance in the Growing GLP-1 Market October 22, 2024
